Last reviewed · How we verify
NCT05405335: COVID-19
Effect of Prone Positioning on the Severity of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome.
NA trial testing Prone Positioning Maneuver in COVID-19 Acute Respiratory Distress Syndrome in 72 participants. Completed in 28 February 2022.
28 February 2022
Quick facts
| Lead sponsor | Ayub Medical College, Abbottabad |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 72 |
| Start date | 15 October 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 28 February 2022 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Prone Positioning Maneuver
Conditions studied
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
- COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →
- Prone Positioning — all drugs for Prone Positioning →
Sponsor
Ayub Medical College, Abbottabad
Who can join
Eligibility, any sex, with COVID-19 Acute Respiratory Distress Syndrome or COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With this research, we are aiming at finding out the effectiveness of prone positioning in this region population affected by moderate pneumonia due to covid 19 infection so that the hospital staff and doctors may be encouraged with facts and data to use such an easy maneuver to stabilize patient's oxygen saturation as we believe that prone positioning does have a protective effect against severe disease and has an effect on reducing mortality if patients are encouraged for prone positioning with proper technique and for suitable time duration as has been observed in the clinical practice in the covid wards. Therefore, we want to assess the effects of 8 hours per day prone positioning the patients with confirmed covid pneumonia admitted in the covid wards.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05405335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
- NCT04896853 — Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05405335 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ayub Medical College, Abbottabad
- Last refreshed: 8 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05405335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing